Determining the optimal timing of disease-modifying therapies for neurodegenerative disorders will necessitate identification of when the underlying pathobiological process becomes active, well in advance of the point at which clinical manifestions appear. Phenoconversion, the emergence of clinically manifest syndomes,...
Michael J. Strong, Neil S. Donison, A. Al-Chalabi et al.· Brain : a journal of neurolo...· 0 citations
Recent proteomic studies have identified both established and novel proteins in genetic frontotemporal lobar degeneration (FTLD). However, it remains unclear at what point in the disease these proteins deviate from normal levels and how their trajectories relate to one another. Defining the temporal sequence of p...
J. D. De Houwer, Wenjie Kang, Renee van Buuren et al.· Alzheimer's Research & T...· 0 citations
Machine-learning stratification of genetic FTD reveals a progressive and a dissociated disease track and provides individualized progression scores that closely track clinical status, enabling smaller, more efficient prevention and early-intervention trials than conventional MRI or NfL markers alone.
M. Soltaninejad, Y. Iturria-Medina, A. Bouzigues et al.· bioRxiv· 0 citations
Sex and educational attainment significantly affect the development and maintenance of cognitive reserve in individuals with genetic FTD, and underscore the importance of identifying disease-modifying interventions since the presymptomatic stages of the disease.
E. Premi, Damiano Archetti, A. Redolfi et al.· Brain Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
